No Detail Found!

Predictive Value of HBsAg for O -treatment Response in HBeAg-negative Chronic Hepatitis B Patients

Author(s)
Xiaoping Fan Department of Infectious Disease and Hepatology, The Second Hospital of Shandong University, Jinan, China; Department of Hepatology, Qingdao Sixth People’s Hospital, Qingdao, China
Tao Li Department of Infectious Disease and Hepatology, The Second Hospital of Shandong University, Jinan, China
Feng Liu Department of Hepatology, Tianjin Second People’s Hospital, Tianjin, China
Lixin Zhang Department of Infectious Disease and Hepatology, The Second Hospital of Shandong University, Jinan, China
Baohua Yang Department of Infectious Disease and Hepatology, The Second Hospital of Shandong University, Jinan, China
Lei Wang Department of Infectious Disease and Hepatology, The Second Hospital of Shandong University, Jinan, China
Abstract
Objective: To investigate the virological relapse (VR) rate and prognostic value of the HBsAg level at treatment completion for predicting sustained o -treatment response in HBeAg-negative patients after neucleos(t)ide analog (NA) therapy. Study Design: Prospective observational cohort study. Place and Duration of Study: The Second Hospital of Shandong University, Ji nan, China, between December 2001 and January 2020. Methodology: Eighty-one HBeAg-negative chronic hepatitis B patients who stopped NA treatment were included. Factors associated with the VR were identi ed using univariate and multivariate Cox regression models. Results: Of the 81 patients, 42 had sustained o -treatment response with a median follow-up of 60.0 months (interquartile range [IQR] 33.0 111.0 months). Thirty-nine patients relapsed and 32 relapsed within the rst year. The cumulative VR rates were 34.6%, 41.0%, 42.5%, 48.1%, and 55.8% at 1, 2, 3, 5, and 10 years o -therapy, respectively. For patients with end-oftreatment (EOT) HBsAg <250 IU/mL, the 10-year cumulative VR rate was 26.0%. Time to HBV DNA negativity (median, 2 months [IQR 1.0 3.0 months]) and age at EOT were also independent predictors of sustained o -treatment response. Conclusion: Discontinuing long-term NA treatment is a feasible option for HBeAg-negative chronic hepatitis B patients whose HBsAg levels are low, and HBsAg <250 IU/mL may be an acceptable cut-o value. Younger age at EOT and shorter time to HBV DNA negativity are also independent factors associated with sustained o -treatment response.
Publication Details
Page(s) 51-56
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Relapse, Hepatitis B Surface Antigen, Cessation, Nucleos(t)ide analogs
0

Citations

0

Downloads

96

Views